Teva’s Ecopipam NDA Looks Like a Pipeline Win. The Commercial Math Is More Complicated.
Teva filed an NDA for ecopipam, a first-in-class pediatric Tourette therapy, but orphan drug status and $15B in debt...
Ecopipam
Teva filed an NDA for ecopipam, a first-in-class pediatric Tourette therapy, but orphan drug status and $15B in debt...